GSK reaffirmed its core earnings per share growth target of 7-9% by 2026, supported by strong sales of key drugs like Nucala, Dovato, and Jemperli. A new product, Exdensur, a twice-yearly maintenance treatment for severe asthma, generated $15 million in sales in its first full quarter after FDA approval, potentially adding to GSK's growth drivers. Despite a recent stock price pullback following mixed Q1 results, GSK's dividend yield of 3.46% remains attractive compared to peers. The company’s risk/reward profile is seen as favorable due to its diverse portfolio and growth prospects.
UBS maintains a neutral rating on GSK ahead of its Q2 results, focusing on CEO Luke Miels' upcoming strategy update. UBS expects little market reaction to the earnings, highlighting concerns over a £4 billion gap between GSK's sales target and foreca...
UBS maintains a neutral rating on GSK ahead of its Q2 results and a strategy update from new CEO Luke Miels, focusing on whether he can deliver GSK's target of over £40 billion in risk-adjusted sales by 2031. UBS forecasts slightly below consensus fo...
